上海谊众9月15日获融资买入3388.14万元，融资余额6.23亿元

Group 1 - Shanghai Yizhong's stock price increased by 3.59% on September 15, with a trading volume of 429 million yuan [1] - The financing buy-in amount for Shanghai Yizhong on the same day was 33.88 million yuan, while the financing repayment was 30.57 million yuan, resulting in a net financing buy-in of 3.32 million yuan [1] - As of September 15, the total financing and securities lending balance for Shanghai Yizhong was 624 million yuan [1] Group 2 - The financing balance for Shanghai Yizhong is 623 million yuan, accounting for 4.97% of its circulating market value, which is above the 90th percentile level over the past year [1] - On the same day, Shanghai Yizhong repaid 1,267 shares in securities lending and sold 1,800 shares, with a selling amount of 109,100 yuan [1] - The securities lending balance is 957,400 yuan, which is below the 40th percentile level over the past year [1] Group 3 - As of June 30, the number of shareholders for Shanghai Yizhong was 6,521, an increase of 6.14% from the previous period [2] - The average circulating shares per person decreased by 5.78% to 31,698 shares [2] - For the first half of 2025, Shanghai Yizhong achieved operating revenue of 160 million yuan, a year-on-year increase of 31.48%, and a net profit attributable to shareholders of 38.00 million yuan, a year-on-year increase of 10.13% [2] Group 4 - Since its A-share listing, Shanghai Yizhong has distributed a total of 92.23 million yuan in dividends [2] - The company specializes in the research and industrialization of modified new drugs for anti-tumor treatments, with its main revenue source being the injectable paclitaxel polymer micelle, accounting for 99.84% of its total revenue [1]